Israel Englander’s ALX Oncology ALXO Stock Holding History

Israel Englander’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$113K	–	5663
2025 Q4	$113K	Buy	100,000 +59,100	+144%	+$89.5K	﹤0.01%	5609
2025 Q3	$74.8K	Buy	+40,900	New	+$35.4K	﹤0.01%	5764
2025 Q1	–	Sell	-125,000	Closed	-$209K	–	5807
2024 Q4	$209K	Buy	+125,000	New	+$192K	﹤0.01%	5283
2024 Q3	–	Sell	-130,000	Closed	-$784K	–	6058
2024 Q2	$784K	Buy	130,000 +100,000	+333%	+$1.23M	﹤0.01%	4278
2024 Q1	$335K	Sell	30,000 -11,600	-28%	-$163K	﹤0.01%	5063
2023 Q4	$619K	Sell	41,600 -118,800	-74%	-$1.13M	﹤0.01%	4515
2023 Q3	$770K	Buy	160,400 +109,900	+218%	+$596K	﹤0.01%	4366
2023 Q2	$379K	Buy	+50,500	New	+$331K	﹤0.01%	4734
2021 Q2	–	Sell	-9,000	Closed	-$664K	–	6475
2021 Q1	$664K	Buy	+9,000	New	+$708K	﹤0.01%	4582

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Israel Englander's ALXO Position: Q2 2026 in Review

Israel Englander reduced its ALX Oncology (ALXO) stake by 22% in Q2 2026, selling an estimated $796K and leaving 1,543,594 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

Israel Englander first reported a position in ALXO in Q2 2021 and has held it in 18 quarters since. The position peaked at $7.99M in Q2 2024. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Israel Englander held 1,543,594 shares of ALX Oncology worth $3.2M as of Q2 2026.
Israel Englander sold 444,965 ALX Oncology shares in Q2 2026, an estimated $796K.
ALX Oncology made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3408 holding.
Israel Englander first reported a position in ALX Oncology in Q2 2021 and has held it in 18 quarters since.
Israel Englander's ALX Oncology position peaked at $7.99M in Q2 2024.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.